{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:40:23Z","timestamp":1789155623761,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish State support for Clinical Research","award":["ALFGBG-717531, ALFGBG-715986, and ALFGBG-720931"],"award-info":[{"award-number":["ALFGBG-717531, ALFGBG-715986, and ALFGBG-720931"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS094067"],"award-info":[{"award-number":["R01 NS094067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12974-019-1404-9","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T08:03:11Z","timestamp":1548316991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection"],"prefix":"10.1186","volume":"16","author":[{"given":"Linn","family":"Hermansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-5828","authenticated-orcid":false,"given":"Aylin","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"1404_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11904-010-0070-4","volume":"8","author":"V Valcour","year":"2011","unstructured":"Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV\/AIDS Rep. 2011;8:54\u201361.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"1404_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12068","volume":"254","author":"TH Burdo","year":"2013","unstructured":"Burdo TH, Lackner A, Williams KC. Monocyte\/macrophages and their role in HIV neuropathogenesis. Immunol Rev. 2013;254:102\u201313.","journal-title":"Immunol Rev"},{"key":"1404_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nri1527","volume":"5","author":"F Gonz\u00e1lez-Scarano","year":"2005","unstructured":"Gonz\u00e1lez-Scarano F, Mart\u00edn-Garc\u00eda J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69\u201381.","journal-title":"Nat Rev Immunol"},{"key":"1404_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00002030-199901140-00003","volume":"13","author":"R Brach-Werner","year":"1999","unstructured":"Brach-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS. 1999;13:1\u201322.","journal-title":"AIDS"},{"key":"1404_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/00002030-199509000-00004","volume":"9","author":"A Ranki","year":"1995","unstructured":"Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS. 1995;9:1001\u20138.","journal-title":"AIDS"},{"key":"1404_CR6","doi-asserted-by":"publisher","first-page":"9456","DOI":"10.1523\/JNEUROSCI.1460-11.2011","volume":"31","author":"EA Eugenin","year":"2011","unstructured":"Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci. 2011;31:9456\u201365.","journal-title":"J Neurosci"},{"key":"1404_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrn2040","volume":"8","author":"R Ellis","year":"2007","unstructured":"Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33\u201344.","journal-title":"Nat Rev Neurosci"},{"key":"1404_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/35073667","volume":"410","author":"M Kaul","year":"2001","unstructured":"Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988\u201394.","journal-title":"Nature"},{"key":"1404_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11904-014-0255-3","volume":"12","author":"Z Zayyad","year":"2015","unstructured":"Zayyad Z, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Current HIV\/AIDS Reports. 2015;12:16\u201324.","journal-title":"Current HIV\/AIDS Reports"},{"key":"1404_CR10","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1097\/QAD.0b013e32828e4e27","volume":"21","author":"KR Robertson","year":"2007","unstructured":"Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915\u201321.","journal-title":"AIDS"},{"key":"1404_CR11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1212\/WNL.0b013e3181f4d5bb","volume":"75","author":"P Vivithanaporn","year":"2010","unstructured":"Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, et al. Neurologic disease burden in treated HIV\/AIDS predicts survival: a population-based study. Neurology. 2010;75:1150\u20138.","journal-title":"Neurology"},{"key":"1404_CR12","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/clinchem\/35.8.1746","volume":"35","author":"D Fuchs","year":"1989","unstructured":"Fuchs D, Spira TJ, Hausen A, Reibnegger G, Werner ER, Felmayer GW, et al. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem. 1989;35:1746\u20139.","journal-title":"Clin Chem"},{"key":"1404_CR13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1189\/jlb.72.6.1148","volume":"72","author":"B Wirleitner","year":"2002","unstructured":"Wirleitner B, Reider D, Ebner S, B\u00f6ck G, Widner B, Jaeger M, et al. Monocyte-derived dendritic cells release neopterin. J Leukoc Biol. 2002;72:1148\u201353.","journal-title":"J Leukoc Biol"},{"key":"1404_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1742-6405-7-15","volume":"7","author":"L Hagberg","year":"2010","unstructured":"Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.","journal-title":"AIDS Res Ther"},{"key":"1404_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1742-2094-10-62","volume":"10","author":"A Yilmaz","year":"2013","unstructured":"Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation. 2013;10:62.","journal-title":"J Neuroinflammation"},{"key":"1404_CR16","doi-asserted-by":"publisher","first-page":"e0157160","DOI":"10.1371\/journal.pone.0157160","volume":"11","author":"A Ed\u00e9n","year":"2016","unstructured":"Ed\u00e9n A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One. 2016;11:e0157160.","journal-title":"PLoS One"},{"key":"1404_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-59745-447-6_7","volume":"511","author":"A Roslind","year":"2009","unstructured":"Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol. 2009;511:159\u201384.","journal-title":"Methods Mol Biol"},{"key":"1404_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2217\/fon.09.66","volume":"5","author":"JS Johansen","year":"2009","unstructured":"Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol. 2009;5:1065\u201382.","journal-title":"Future Oncol"},{"key":"1404_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/rheumatology\/38.7.618","volume":"38","author":"J Johansen","year":"1999","unstructured":"Johansen J, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology. 1999;38:618\u201326.","journal-title":"Rheumatology"},{"key":"1404_CR20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00384-002-0446-z","volume":"18","author":"I Koutroubakis","year":"2003","unstructured":"Koutroubakis I, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis A, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Color Dis. 2003;18:254\u20139.","journal-title":"Int J Color Dis"},{"key":"1404_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1084\/jem.20081271","volume":"206","author":"CG Lee","year":"2009","unstructured":"Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of breast regression protein 39 (BRP-39)\/chitinase 3-like-1 in Th2 and IL-13\u2013induced tissue responses and apoptosis. J Exp Med. 2009;206:1149\u201366.","journal-title":"J Exp Med"},{"key":"1404_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:903\u201312.","journal-title":"Biol Psychiatry"},{"key":"1404_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2014.02.004","volume":"269","author":"C Malmestr\u00f6m","year":"2014","unstructured":"Malmestr\u00f6m C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol. 2014;269:87\u20139.","journal-title":"J Neuroimmunol"},{"key":"1404_CR24","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2174\/1570159X15666170208124324","volume":"15","author":"P Muszynski","year":"2017","unstructured":"Muszynski P, Groblewska M, Kulcynska-Przybik A, Kulakowska A, Mroczko B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer\u2019s disease. Curr Neuropharmacol. 2017;15:906\u201317.","journal-title":"Curr Neuropharmacol"},{"key":"1404_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2353\/ajpath.2008.080389","volume":"173","author":"DL Kolson","year":"2008","unstructured":"Kolson DL. YKL-40: a candidate biomarker for simian immunodeficiency virus and human immunodeficiency virus encephalitis? Am J Pathol. 2008;173:25\u20139.","journal-title":"Am J Pathol"},{"key":"1404_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1742-2094-7-34","volume":"7","author":"D Bonneh-Barkay","year":"2010","unstructured":"Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7:34.","journal-title":"J Neuroinflammation"},{"key":"1404_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22:530\u201346.","journal-title":"Brain Pathol"},{"key":"1404_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2353\/ajpath.2008.080045","volume":"173","author":"D Bonneh-Barkay","year":"2008","unstructured":"Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GCB, Darko SW, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol. 2008;173:130\u201343.","journal-title":"Am J Pathol"},{"key":"1404_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/QAD.0000000000001314","volume":"31","author":"MJ Peluso","year":"2017","unstructured":"Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JLK, Chalermchai T, et al. Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS. 2017;31:247\u201352.","journal-title":"AIDS"},{"key":"1404_CR30","unstructured":"Janssen RS, Cornblath DR, Epstein LG, Foa RP, McArthur JC, Price RW, Tross S. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778-785."},{"key":"1404_CR31","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789\u201399.","journal-title":"Neurology"},{"key":"1404_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017;17:761\u201370.","journal-title":"Expert Rev Mol Diagn"},{"key":"1404_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ana.21697","volume":"66","author":"MJ Churchill","year":"2009","unstructured":"Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus - associated dementia. Ann Neurol. 2009;66:253\u20138.","journal-title":"Ann Neurol"},{"key":"1404_CR34","doi-asserted-by":"publisher","first-page":"e88591","DOI":"10.1371\/journal.pone.0088591","volume":"9","author":"JJ Krut","year":"2014","unstructured":"Krut JJ, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014;9:e88591.","journal-title":"PLoS One"},{"key":"1404_CR35","doi-asserted-by":"publisher","first-page":"e116081","DOI":"10.1371\/journal.pone.0116081","volume":"9","author":"J Peterson","year":"2014","unstructured":"Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One. 2014;9:e116081.","journal-title":"PLoS One"},{"key":"1404_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2016.08.004","volume":"299","author":"MA Ma\u00f1\u00e9-Mart\u00ednez","year":"2016","unstructured":"Ma\u00f1\u00e9-Mart\u00ednez MA, Olsson B, Bau L, Matas E, Cobo-Calvo \u00c1, Andreasson U, et al. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J Neuroimmunol. 2016;299:112\u20137.","journal-title":"J Neuroimmunol"},{"key":"1404_CR37","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1212\/NXI.0000000000000300","volume":"3","author":"B Anesten","year":"2016","unstructured":"Anesten B, Yilmaz A, Hagberg L, Zetterberg H, Nilsson S, Brew BJ, et al. Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurol Neuroimmunol NeuroInflamm. 2016;3:e300.","journal-title":"Neurol Neuroimmunol NeuroInflamm"},{"key":"1404_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/0167-5699(88)91203-0","volume":"9","author":"D Fuchs","year":"1988","unstructured":"Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988;9:150\u20135.","journal-title":"Immunol Today"},{"key":"1404_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neulet.2008.04.046","volume":"438","author":"OD Cano","year":"2008","unstructured":"Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A. Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. Neurosci Lett. 2008;438:22\u20135.","journal-title":"Neurosci Lett"},{"key":"1404_CR40","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1212\/NXI.0000000000000512","volume":"6","author":"M Gissl\u00e9n","year":"2019","unstructured":"Gissl\u00e9n M, Heslegrave A, Veleva E, Yilmaz A, Andersson L-M, Hagberg L, et al. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurol Neuroimmunol NeuroInflamm. 2019;6:e512.","journal-title":"Neurol Neuroimmunol NeuroInflamm"},{"key":"1404_CR41","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","volume":"19","author":"X Chen","year":"2018","unstructured":"Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer\u2019s disease, Parkinson\u2019s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol. 2018;19:2122.","journal-title":"Front Immunol"},{"key":"1404_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s15010-004-3048-6","volume":"32","author":"B Sporer","year":"2004","unstructured":"Sporer B, Missler U, Magerkurth O, Koedel U, Wiesmann M, Pfister HW. Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker for HIV-associated dementia. Infection. 2004;32:20\u20133.","journal-title":"Infection"},{"key":"1404_CR43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1089\/aid.1998.14.1065","volume":"14","author":"LM Andersson","year":"1998","unstructured":"Andersson LM, Fredman P, Lekman A, Rosengren L, Gissl\u00e9n M. Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. AIDS Res Hum Retrovir. 1998;14:1065\u20139.","journal-title":"AIDS Res Hum Retrovir"},{"key":"1404_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1386-6532(01)00196-2","volume":"22","author":"LA Pemberton","year":"2001","unstructured":"Pemberton LA, Brew BJ. Cerebrospinal fluid S-100\u03b2 and its relationship with AIDS dementia complex. J Clin Virol. 2001;22:249\u201353.","journal-title":"J Clin Virol"},{"key":"1404_CR45","first-page":"130","volume":"13","author":"A Green","year":"1999","unstructured":"Green A, Giovannoni G, Miller R, Harrison M, EJ T. Cerebrospinal fluid S-100b concentrations in patients with HIV infection. AIDS. 1999;13:130\u201340.","journal-title":"AIDS"},{"key":"1404_CR46","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1086\/518043","volume":"195","author":"M Gissl\u00e9n","year":"2007","unstructured":"Gissl\u00e9n M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis. 2007;195:1774\u20138.","journal-title":"J Infect Dis"},{"key":"1404_CR47","doi-asserted-by":"publisher","first-page":"ofx108","DOI":"10.1093\/ofid\/ofx108","volume":"4","author":"T Booiman","year":"2017","unstructured":"Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, et al. High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in cerebrospinal fluid. Open Forum Infect Dis. 2017;4:ofx108.","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1404-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1404-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1404-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T04:11:37Z","timestamp":1694578297000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1404-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1404"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1404-9","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"26 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Ethics Review Board in Gothenburg, Sweden (\u00d6588-01) and was performed in accordance with the Helsinki Declaration. All participants gave their informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served on scientific advisory boards for Eli Lilly, Roche Diagnostics, and Wave; he has received travel grants from Teva; and he is also a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg.KB has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics. He is also a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"16"}}